IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishAlterations in the transcriptional factor c-MYC could be involved in the anti-EGFR resistance in metastatic colorectal cancer (mCRC). The c-MYC expression was evaluated in 121 RAS and BRAF wild-type mCRC before treatment with anti-EGFR+Folfiri therapy and in 33 subsequent metastases collected during target therapy (TT) or in TT resistance phase. We analyzed the expression and the functional role of some c-MYC linked miRNAs (miR-31-3p, miR-143 and miR-145) in our patient group and in two CRC cell lines, also performing a c-MYC target PCR array. Patients with higher c-MYC expression (HME) showed a significant lower PFS and OS when compared to those with low c-MYC expression (LME). HME pattern was significantly more frequent in the metastases after TT and significantly associated to anti-EGFR molecular resistance alterations. We also found a significant correlation between the expression of the above-mentioned c-MYC linked miRNAs, c-MYC level and anti-EGFR resistance. Moreover, expression gene profiling pointed out the pivotal role of c-MYC in CRC-related cell-cycle, apoptosis, signal transduction and cell-growth pathways. c-MYC expression might distinguish patients with a lower PFS and OS in anti-EGFR treated mCRC. The individuation of some miRNAs involved in the c-MYC pathway regulation and the downstream c-MYC effector genes could provide a new possible target to overcome the anti-EGFR resistance in mCRC.
Strippoli, A., Cocomazzi, A., Basso, M., Cenci, T., Ricci, R., Pierconti, F., Cassano, A., Fiorentino, V., Barone, C., Bria, E., Ricci-vitiani, L., Tortora, G., Larocca, L. M., Martini, M., C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors, <<CANCERS>>, 2020; 12 (3): 638-656. [doi:10.3390/cancers12030638] [http://hdl.handle.net/10807/153450]
| Autori: | ||
| Titolo: | C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.3390/cancers12030638 | |
| Data di pubblicazione: | 2020 | |
| Abstract: | Alterations in the transcriptional factor c-MYC could be involved in the anti-EGFR resistance in metastatic colorectal cancer (mCRC). The c-MYC expression was evaluated in 121 RAS and BRAF wild-type mCRC before treatment with anti-EGFR+Folfiri therapy and in 33 subsequent metastases collected during target therapy (TT) or in TT resistance phase. We analyzed the expression and the functional role of some c-MYC linked miRNAs (miR-31-3p, miR-143 and miR-145) in our patient group and in two CRC cell lines, also performing a c-MYC target PCR array. Patients with higher c-MYC expression (HME) showed a significant lower PFS and OS when compared to those with low c-MYC expression (LME). HME pattern was significantly more frequent in the metastases after TT and significantly associated to anti-EGFR molecular resistance alterations. We also found a significant correlation between the expression of the above-mentioned c-MYC linked miRNAs, c-MYC level and anti-EGFR resistance. Moreover, expression gene profiling pointed out the pivotal role of c-MYC in CRC-related cell-cycle, apoptosis, signal transduction and cell-growth pathways. c-MYC expression might distinguish patients with a lower PFS and OS in anti-EGFR treated mCRC. The individuation of some miRNAs involved in the c-MYC pathway regulation and the downstream c-MYC effector genes could provide a new possible target to overcome the anti-EGFR resistance in mCRC. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Strippoli, A., Cocomazzi, A., Basso, M., Cenci, T., Ricci, R., Pierconti, F., Cassano, A., Fiorentino, V., Barone, C., Bria, E., Ricci-vitiani, L., Tortora, G., Larocca, L. M., Martini, M., C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors, <<CANCERS>>, 2020; 12 (3): 638-656. [doi:10.3390/cancers12030638] [http://hdl.handle.net/10807/153450] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
| File | Descrizione | Tipologia | Note | Licenza | |
|---|---|---|---|---|---|
| c-Myc cancers-12-00638.pdf | Versione Editoriale (PDF) | Nessuna Nota |  | Open Access Visualizza/Apri |
Copyright © 2021